Pharmos seeks gout bandwagon partner in last-chance saloon
This article was originally published in Scrip
Executive Summary
The Iselin, New Jersey firm Pharmos is touting positive data from a proof-of-concept trial of its last remaining pipeline product in the hope of cashing in on the gout goldrush before its own purse is empty. The company has developed levotofisopam, an S-enantiomer of the benzodiazepine tofisopam, for the treatment of gout, and is hoping that a partner will step forward for the drug.